Detail akcie IONBEAM APPL online

Business Summary: Ion Beam Applications SA (IBA) is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Ion Beam Applications SA revenues increased 7% to EUR498.2M. Net income totaled EUR9.3M vs. loss of EUR9.1M. Revenues reflect Protontherapy segment increase of 19% to EUR436.3M, Rest of the world segment increase of 9% to EUR337.5M. Net Income reflects Protontherapy segment income totaling EUR16.1M vs. loss of EUR636K. Dividend per share increased from EUR0.12 to EUR0.20.